Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Podcasts

Olaparib Maintenance Therapy for gBRCA-Mutated Pancreatic Cancer

Recapping a late-breaking abstract from the annual ASCO meeting, Ghassan Abou-Alfa, MD, discusses the POLO trial of olaparib for the treatment of gBRCA-mutated, metastatic pancreatic cancer.

Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer.

 

 

Advertisement

Advertisement

Advertisement

Advertisement